A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
對再生元製藥公司的23位分析師推薦再仔細研究
The standing of Regeneron Pharmaceuticals among financial...23 analysts have shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近三個月中，有23位分析師對再生元製藥公司（納斯達克股票代碼：REGN）進行了評估，表達了買入和看淡的不同觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $1185.96, accompanied by a high estimate of $1300.00 and a low estimate of $1015.00. Highlighting a 0.1% decrease, the current average has fallen from the previous average price target of $1187.13.
分析師最近對再生元製藥公司進行了評估，並提供了12個月的目標價格。平均目標價格爲$1185.96，最高估價爲$1300.00，最低估價爲$1015.00。當前的平均值與之前的平均目標價格$1187.13相比下降了0.1%。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析：詳細分析
The standing of Regeneron Pharmaceuticals among financial...
通過對最近分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間